Jim Cramer is bullish on Novartis AG, Sirius XM Radio, Coupa Software and Juno Therapeutics.
Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.
Here's what moving in the world of Biotech
The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.
FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer.